home / stock / abus / abus articles

ABUS Articles, Arbutus Biopharma Corporation

Stock Information
Company Name: Arbutus Biopharma Corporation
Stock Symbol: ABUS
Market: NASDAQ
Website: arbutusbio.com
Menu
ABUS ABUS Quote ABUS Short ABUS News ABUS Articles ABUS Message Board
Get ABUS Alerts

News, Short Squeeze, Breakout and More Instantly...
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update | Benzinga

WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company lever...
Arbutus to Participate in Jefferies Global Healthcare Conference | Benzinga

WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company levera...

Arbutus to Present Imdusiran Data at EASL Congress 2024 | Benzinga

WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 | Benzinga

WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update | Benzinga

WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leve...

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge | Benzinga

A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement cas...

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna | Benzinga

WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leve...
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update | Benzinga

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company lever...

Arbutus to Present at Jefferies London Healthcare Conference | Benzinga

WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bi...

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Benzinga

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdus...
Next 10